Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study

Heidi E. Kosiorek, Robyn M. Scherber, Holly L. Geyer, Srdan Verstovsek, Blake T. Langlais, Gina L. Mazza, Jason Gotlib, Vikas Gupta, Leslie J. Padrnos, Jeanne M. Palmer, Angela Fleischman, Ruben A. Mesa, Amylou C. Dueck

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1065-1068
Number of pages4
JournalBritish Journal of Haematology
Volume198
Issue number6
DOIs
StatePublished - Sep 2022
Externally publishedYes

Keywords

  • myelofibrosis
  • prognostic factors
  • quality of life
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this